VX-765: Selective Caspase-1 Inhibitor for Inflammation Research

Executive Summary: VX-765 is a well-characterized, orally absorbed pro-drug that selectively inhibits caspase-1, a key mediator of inflammatory cytokine maturation and pyroptosis. Its active metabolite, VRT-043198, blocks the conversion of pro-IL-1β and pro-IL-18 into their active forms, significantly reducing inflammatory responses in vitro and in vivo (Israelov et al., 2020). VX-765 does not alter levels of other cytokines such as IL-6 or TNFα, ensuring pathway specificity. Preclinical models confirm its efficacy in diverse inflammatory conditions, including blood-brain barrier (BBB) injury and rheumatoid arthritis. APExBIO offers VX-765 (SKU A8238) as a high-purity research product, facilitating reproducible caspase-1 pathway investigations [Product Page].

Biological Rationale

Caspase-1, also known as interleukin-1 converting enzyme (ICE), is a cysteine protease that orchestrates the maturation and secretion of key inflammatory cytokines IL-1β and IL-18 (Israelov et al., 2020). Activation of caspase-1 occurs within the inflammasome complex in response to pathogenic or danger signals. Upon activation, caspase-1 cleaves pro-IL-1β and pro-IL-18, generating their biologically active forms that drive acute and chronic inflammation. Excessive or dysregulated caspase-1 activity contributes to pathological inflammation, endothelial barrier disruption, and cell death via pyroptosis. Selective inhibition of caspase-1 is therefore a validated approach to dissecting inflammatory mechanisms and modeling immune-mediated cell death (See also: VX-765: Selective Caspase-1 Inhibitor for Inflammation Research). This article extends previous summaries by integrating new evidence from blood-brain barrier injury models and highlighting updated workflow parameters.

Mechanism of Action of VX-765

VX-765 is an orally bioavailable pro-drug that is rapidly converted in vivo to its active metabolite, VRT-043198 (APExBIO Product Page). VRT-043198 binds selectively to the catalytic site of caspase-1, inhibiting its proteolytic activity. This blocks the cleavage of pro-IL-1β and pro-IL-18, preventing their secretion and downstream inflammatory signaling. VX-765 does not inhibit other caspase family members at relevant concentrations, maintaining selectivity for the ICE/caspase-1 sub-family. Inhibition of caspase-1 by VX-765 also suppresses caspase-1-dependent pyroptotic cell death in macrophages and lymphoid tissues (See also: VX-765: Advancing Caspase-1 Inhibition in Inflammation and Pyroptosis). This article details how these mechanistic insights inform translational research in neuroinflammation and immune dysregulation.

Evidence & Benchmarks

• Inhibition of caspase-1 by VX-765 restores blood-brain barrier integrity after paraoxon-induced injury in vitro and in vivo (Israelov et al., 2020, https://doi.org/10.1186/s12974-020-01927-w).
• VX-765 reduces secretion of IL-1β and IL-18, but does not affect IL-6, IL-8, TNFα, or IL-α levels in cell-based assays (APExBIO, Product Data).
• Preclinical models of collagen-induced arthritis and skin inflammation demonstrate significant reductions in inflammatory cytokine release with oral VX-765 administration (APExBIO, Product Data).
• In HIV-infected lymphoid tissues, VX-765 prevents dose-dependent pyroptotic death of CD4 T cells (APExBIO, Product Data).
• Enzyme inhibition assays confirm potent caspase-1 inhibition by VRT-043198 at sub-micromolar concentrations in buffered conditions (pH 7.5) (APExBIO, Protocols).
• Restoration of VE-cadherin and suppression of ICAM-1/E-selectin upregulation in BBB endothelial cells observed after VX-765 treatment (Israelov et al., 2020, DOI).

For additional protocol guidance and workflow integration, see VX-765 (SKU A8238): Precision Caspase-1 Inhibitor for Reliable Assays, which this article expands by addressing new CNS applications and BBB-specific endpoints.

Applications, Limits & Misconceptions

VX-765 is widely used in research on:

• Inflammasome pathway analysis and caspase-1 signaling.
• Pyroptosis studies in macrophages and T cells.
• Modeling inflammatory diseases, including rheumatoid arthritis, CNS injury, and viral infection.
• Preclinical evaluation of anti-inflammatory therapeutics.

Common Pitfalls or Misconceptions

• VX-765 is not a pan-caspase inhibitor; it does not inhibit caspase-8, -9, or other ICE-like proteases at relevant doses (Israelov et al., 2020).
• It does not reduce levels of cytokines such as IL-6, IL-8, or TNFα, which are regulated independently of caspase-1 (APExBIO Product Data).
• Water solubility is negligible; VX-765 must be dissolved in DMSO or ethanol for stock solutions (APExBIO Product Page).
• Long-term storage in solution is not recommended; solutions should be prepared fresh and stored at -20°C desiccated for short-term use only.
• Therapeutic claims in humans remain investigational; all results are preclinical or in vitro.

This article clarifies the mechanistic boundaries of VX-765, building on overviews such as VX-765 and the Next Frontier in Selective Caspase-1 Inhibition, by specifying non-target cytokines and off-target enzyme limits.

Workflow Integration & Parameters

The recommended workflow for VX-765 (SKU A8238, APExBIO) involves dissolution in DMSO (≥313 mg/mL) or ethanol (≥50.5 mg/mL with ultrasonic assistance). Working dilutions should be prepared in buffered aqueous solutions at pH 7.5, often with additives (e.g., BSA, reducing agents) to stabilize enzyme activity. Enzyme inhibition assays typically use sub-micromolar VX-765 in a 96-well format, with controls for solvent and off-target effects. For cell-based studies, dose-response experiments should be conducted, with endpoint measurements of IL-1β and IL-18 release via ELISA or immunoassay. Storage of solid VX-765 requires desiccation at -20°C. Solutions should be used within days to ensure compound integrity. For detailed assay protocols and troubleshooting, see VX-765 (SKU A8238): Precision Caspase-1 Inhibitor for Reliable Assays.

Conclusion & Outlook

VX-765, as supplied by APExBIO, is a benchmark tool for dissecting caspase-1-dependent inflammatory pathways, offering high selectivity and robust, reproducible results in preclinical models. Its mechanism of action and workflow compatibility have been rigorously validated, particularly in BBB and immune cell contexts. Ongoing research is extending its use to new disease models, including CNS disorders and viral pathologies. For detailed product specifications and ordering, see the VX-765 product page. This article refines and extends the application scope outlined in VX-765: Selective Oral Caspase-1 Inhibitor for Inflammatory Research by integrating the latest CNS inflammation data and workflow standards.